The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects

B Salehian; J Bilas; V Mahabadi; V Aleli; K Norris; SH Bhasin

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects

Author(s):

B Salehian

^1,*,

J Bilas²,

V Mahabadi²,

V Aleli²,

K Norris²,

SH Bhasin²

1Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, [email protected], CA, USA

2Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, CA, USA

International Journal of Endocrinology and Metabolism:Vol. 6, issue 4; 162-174

Published online:Oct 31, 2008

Article type:Research Article

Received:Jul 16, 2008

Accepted:Nov 23, 2008

How to Cite:Salehian B, Bilas J, Mahabadi V, Aleli V, Norris K, et al. The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects. Int J Endocrinol Metab. 2008;6(4):. doi:

Abstract

We examined the hypothesis that the PPAR Gamma activator, Pioglitazone, has a fat depot specific effect and aimed at determining the ef fects of pioglitazone on changes in total and regional fat distribution, serum adiponectin levels, carotid artery intimal thickness, and subcutaneous adipose tissue histology in otherwise healthy obese men and women from a minority population.

Materials and Methods: This is a doubleblind, randomized, controlled trial, single site study of the minority population in south central Los Angeles. Thirtyfive obese, but otherwise healthy, men and women (waisttohip ratio >0.95 for men and >0.85 in women) were randomly assigned into three groups: Group A: placebo; group B, pioglitazone 30 mg/day, and group C, pioglitazone 45 mg/day, for a duration of 6 months. The primary outcome measures were changes in visceral fat as measured by Computerized Tomography scan (CT Scan) of the abdomen and thigh, body composition by Dual energy Xray Absorptiometry Scan (DXA scan) and carotid artery intimamedia thickness as measured by ultrasound. Serum adiponectin levels and the size and number of adipocytes were also measured.

Results: At baseline, mean age, proportion of female participation, race and ethnicity distribution, blood pressure, Body Mass Index (BMI) and anthropometric measures of subjects in the three groups were not statistically different. After 6 months, we observed significant decrease of intramuscular fat and significant increase of subcutaneous thigh fat in groups B and C as compared to group A. The average carotid artery intimal thickness increased in group A (p<0.01), but not in group B, and decreased in group C (p<0.01). Serum adiponectin levels rose sharply (p<0.001) in the treatment groups only. A significant positive correlation was observed between the change of the adiponectin levels and subcutaneous thigh fat. Conclusion: Results of this study supports the use of pioglitazone in the prevention of stroke and peripheral vascular disease in highrisk populations.

Keywords

Full Text

Full text is available in PDF

A Pilot Study of Pioglitazone for the Treatment of Non-Alcoholic Fatty Liver Disease

Abeer Al Gharabally,

Christopher B OBrien,

Rita C Acosta

Gharabally A, OBrien C, Acosta R. A Pilot Study of Pioglitazone for the Treatment of Non-Alcoholic Fatty Liver Disease. Hepat Mon. 2007;7(3):. doi:

21

May

2013

The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial

Mohsen Razavizade,

Raika Jamali,

Abbas Arj,

Seyyed Mohammad Matini,

Alireza Moraveji,

Effat Taherkhani

Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, et al. The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial. Hepat Mon. 2013;13(5):e9270. doi: https://doi.org/10.5812/hepatmon.9270

24

May

2024

The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes

Morteza Aghajanpoor,

Mehrzad Gholampourdehaki,

Reza Mosaed,

Iraj Mirzaii-Dizgah,

Afsaneh Vosughi

Aghajanpoor M, Gholampourdehaki M, Mosaed R, Mirzaii-Dizgah I, Vosughi A. The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes. Ann Mil Health Sci Res. 2024;22(2):e144009. doi: https://doi.org/10.5812/amh-144009

10

Feb

2015

Effect of Walnut Consumption on Serum Lipid Profiles, High-Sensitivity C-Reactive Protein and Nitric Oxide in Patients With Coronary Artery Disease

Giti Kalantarian,

Mohsen Rezaei,

Shahram Homayonfar,

Marzieh Gharibi

Kalantarian G, Rezaei M, Homayonfar S, Gharibi M. Effect of Walnut Consumption on Serum Lipid Profiles, High-Sensitivity C-Reactive Protein and Nitric Oxide in Patients With Coronary Artery Disease. Jentashapir J Cell Mol Biol. 2015;6(1):e27196. doi: https://doi.org/10.5812/jjhr.27196

20

Nov

2019

Combination Low Carbohydrate, High Fat Diet and Physical Activity Intervention on Lipoprotein-Lipids in Type 2 Diabetics

Gerrit Jan Breukelman,

Albertus Kotze Basson,

Trayana Gueorguieva Djarova,

Cornelia Johanna Du Preez,

Ina Shaw,

Brandon Stuwart Shaw

Breukelman GJ, Basson AK, Djarova TG, Du Preez CJ, Shaw I, et al. Combination Low Carbohydrate, High Fat Diet and Physical Activity Intervention on Lipoprotein-Lipids in Type 2 Diabetics. Asian J Sports Med. 2019;10(4):e86905. doi: https://doi.org/10.5812/asjsm.86905

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 0
Last Update: 1 week ago
Scopus by Title (Ref): 1
Last Update: 1 week ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

B Salehian:[PubMed][Scholar]
J Bilas:[PubMed][Scholar]
V Mahabadi:[PubMed][Scholar]
V Aleli:[PubMed][Scholar]
K Norris:[PubMed][Scholar]
SH Bhasin:[PubMed][Scholar]

Research Institute for Endocrine Sciences

Outlines

The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects

Abstract

Full Text

Similar Articles

A Pilot Study of Pioglitazone for the Treatment of Non-Alcoholic Fatty Liver Disease

The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial

The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes

Effect of Walnut Consumption on Serum Lipid Profiles, High-Sensitivity C-Reactive Protein and Nitric Oxide in Patients With Coronary Artery Disease

Combination Low Carbohydrate, High Fat Diet and Physical Activity Intervention on Lipoprotein-Lipids in Type 2 Diabetics

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 2 days ago